Forget Crispr Therapeutics: This Gene-Editing Pick Attracts
The gene-editing field is maturing from hype to real profits. This article outlines why a broader set of players coul...
Focusing on short term investment goals can yield quick financial returns. Discover the right timing for your investment strategy.
27,474 articlesThe gene-editing field is maturing from hype to real profits. This article outlines why a broader set of players coul...
Investors tracking UiPath PATH know 2027 will hinge on cloud adoption, service expansion, and pricing power. This gui...
The S&P 500 has delivered double-digit gains for years, but a new era may bring slower growth and higher costs. This ...
Investors are watching Health Catalyst as healthcare data analytics gain budget priority. This guide breaks down what...
June opened with volatility as Nu Holdings faced a fresh downgrade and a leadership transition. This article breaks d...
A government-contract windfall sparked a sharp rally in Viasat stock. This article breaks down the news, the technolo...
June brought a sharp turn for Newmont as gold dynamics and costs collided with production headwinds. This article bre...
On a day when the market generally slipped, Plug Power captured attention with a solid quarterly report. This piece b...
This article offers a fresh, investor-focused look at american outdoor brands (aout) earnings. It breaks down revenue...
As PacBio lays out its Q1 2026 results, investors hunt for catalysts, cadence, and cash runway signals. This guide tr...
Investors are weighing AI-driven promises against advertising risks as Alphabet and META steer big bets into the futu...
As Bank Montreal prepares to report its Q2 2026 results, investors want clarity on growth, credit quality, and return...